This article is more than 5 years old. Information may no longer be current.

Mundipharma expands Santen partnership

Issue: January 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Mundipharma has expanded a partnership with Santen Pharmaceutical, according to a press release.

The extension of an existing license for Saflutan (tafluprost) will add approximately 50 Middle Eastern and African markets.

In addition, the company will add Taptiqom (tafluprost/timolol) to its license in Canada, Australia, New Zealand, Latin America, the Middle East and Africa.

“We are delighted to further expand our ophthalmic portfolio as well as our successful partnership with Santen, ” Raman Singh, Mundipharma’s CEO, said in the release. “The extended licensing footprint will provide physicians in the additional countries with more preservative-free treatment options for glaucoma patients.”